Skip to main content
. 2023 Nov-Dec;39(6):1847–1852. doi: 10.12669/pjms.39.6.7944

Table-III.

Comparison of clinical effect between the two groups (n,%).

Variables TACE+lenvatinib group (n=46) TACE group (n=57) Fisher P
CR 5 (10.87) 2 (3.51)
PR 27 (58.69) 21 (36.84)
SD 9 (19.57) 24 (42.11)
PD 5 (10.87) 10 (17.54)
Total effective rate 32 (69.57) 23 (40.35) 9.454 <0.05